The CALAsia program will feature plenary sessions, partnering and country specific workshops. The workshops will be aimed attargeting specific topics with a country emphasis on this topic.

June 14, 2009

5:30 p.m. - 7:00 p.m.Registration Open

June 15, 2009

6:30 a.m. - 4:00 p.m.Registration Open

8:00 a.m. - 5:30 p.m.Partnering One x One Meetings

8:00 a.m. - 9:50 a.m.Plenary Session

Plenary Session:

Overview of the Key Markets in the Asia Pacific Region: Opportunities and Challenges for the Biopharmaceutical Industry
Despite the current world economic crisis, Asia and the Pacific Rim region continue to show strong growth potential. These markets, and in particular China and India, are expected to grow into the largest markets in the world over the next few decades along with the U.S. and Japan. In the life sciences, growth in this region is being fueled not only by the size of the market, but also by the quality of R&D and the emergence of companies ready to partner with western companies.

Keynote Presentation:
G. Steven Burrill, CEO, Burrill & Company

Joe Panetta, President and CEO, BIOCOM

Peter Beattie, Former Queensland Premier
Haroon Hashmi, Director, Drug Development - Asia Pacific, Biogen Idec

10:00 a.m. - 11:30 a.m.Workshops


Partnering in Drug Development

We have all heard that India and China are the places to go for cost effective research and clinical trials. This panel will discuss their experiences with outsourcing and what you can expect. They will address the benefits, the quality and challenges. And, what about Australia?

Mario Pennisi, CEO, Queensland Clinical Trials Network Inc.


Dinesh Jain, Founder and CEO, Aagami
Sridhar Mosur, CEO and President, Jubilant Organosys
Sylvie Sakata, Senior Director, Head of External Research Solutions La Jolla Site, Pfizer, Inc.
Masood Tayebi, Executive Chairman, BioDuro LLC
Troy Wilson, CEO, Intellikine


Biolink to Korea: Discovering opportunities in Korea's new biotechnology
This workshop will discuss today's Korea bio and pharmaceutical industry, highlighting three key technologies: Alzheimer/ Analgesics (Non-opioid), Metabolic/Dry-eye syndrome and Biotransformation.

Welcome Remarks:
Sang Chul Kim, General Director, KOTRA Los Angeles
Myung Hwan Park, Executive Director, GyeongGi Bio-Center


Jong Hoon Choi, Executive Director, Korea Biotechnology Industry Organization
Hoon Y. Chung, President and CEO, MedEd Gen Inc.
Kyeong Hoon Jeong, CSO, Mazence
Young Ho Kim, Director, Digital Biotech

11:45 a.m. - 1:55 p.m.Plenary Session

Plenary Session:
Licensing Deals with Asian Partners

Sponsored by: Cooley Godward
This panel will address all aspects of executing a successful licensing deal in Asia including recognizing the cross cultural issues that could potentially threaten a deal and how to with work with partners over a great distance.

John Diekman, Managing Partner, 5AM Ventures

Kay Chandler, Partner, Cooley Godward
Richard Hammel, Partner, International Business Consultants
Leslie Pryce, President, New Business Horizons
Barbara Yanni, Vice President and Chief Licensing Officer, Merck

2:00 p.m. - 3:30 p.m.Workshops

Let's Discuss Innovation in the Asia Pacific Region

It's happening everywhere. Where are the hubs of activity? What are the assets? Can you access these resources?

Charles Hsu, Venture Partner, Bay City Capital

Mark Benedyk, Head, The Pfizer Incubator
Stephen Lam, Senior Manager, Hong Kong Science & Technology Park
Michael Newman, Executive Vice President, Oncology, HUYA Bioscience International
Colleen Coyne Nelson, Professor and Chair, Prostate Cancer Research, Institute of Health and Biomedical Innovation, Queensland University of Technology
Ming-Wei Wang, Director, The National Center for Drug Screening

The Art of Doing Deals in Asia

Yes, It is different but it is also the same. These panelists will discuss their Asian deals and give advice to those companies doing a deal in Asia for the first time.

John Wehrli, Partner, Latham Watkins

Wendy Johnson, Venture Partner, ProQuest Investments
Chris LeMasters, Chief Business Officer, Tragara Pharmaceuticals
Andrew de Guttadauro, Vice President Corporate Development, Vical Incorporated
Micah Zimmerman, Practice Leader, Asia, Scisive Consulting LP

3:30 p.m. - 4:00 p.m.Networking Break

4:00 p.m. - 5:30 p.m.Plenary Session

Plenary Session:
Capital - the Lifeblood of the BioPharmaceutical Industry

Sponsored by: Roth Capital Partners
While science fuels innovation, capital fuels the discovery, development and commercialization of every biopharmaceutical product. This panel will explore the many financing challenges facing our global industry and discuss various options for funding development programs in the current fiscal climate. They will discuss the structural and cultural differences between funding availability options in Asia Pacific and the U.S. for companies located in each region and as well as the potential for funding inter-regional joint ventures or collaborations.

Lisa Walters-Hoffert, Managing Director, Roth Capital Partners

Nancy Chang, Chairman and Sr. Managing Director, Asia, Orbimed Healthcare Fund Management
Juan Harrison, Vice President, Takeda Research Investment, Inc.
Vivian Lee, Partner, Aqua Partners
James Li, Partner, Kleiner Perkins Caufield and Byers

5:30 p.m. - 7:30 p.m.Networking Reception

June 16, 2009

7:30 a.m. - 8:00 a.m.Continental Breakfast

8:00 a.m. - 4:30 p.m.Partnering One x One Meetings

8:00 a.m. - 9:00 a.m.Plenary Session


BayHelix: BioPharmaceutical Perspective
BayHelix Group, business leaders of Chinese heritage in the life sciences and health care community, put forward its perspectives on the development of the biopharmaceutical industry in China through its members and front runners from multinational companies, venture capital firms, CRO, start-ups and law firms.

Wei-Wei Zhang (BayHelix member)

Frank Kung, Managing Partner, Vivo Venture
Kewen Jin, CEO, Charles River China
Marietta Wu, General Manager, Greater China, Burrill & Company
Mang Yu, CEO, NexBio
Dan Zhang, CEO, Fountain Medical
James Zhu, Managing Partner, Perkins Coie Beijing Office

9:00 a.m. - 10:45 a.m.Plenary Session

Plenary Session:
Global Development Strategies: Leveraging the Asia Pacific Region Across the Value Chain

Sponsored by: PriceWaterhouseCoopers
Soaring drug discovery and development costs, a tough regulatory environment, and prolonged time-toapproval, have compelled biopharmaceutical companies to outsource various functions at almost every stage of development to inexpensive but highly skilled destinations organizations in the Asia Pacific region. Leading experts will provide a balanced overview of the forces driving outsourcing to Asia, evolving business models and key considerations and success factors at
every stage of the research and development process. Regional, legal and regulatory differences will be discussed.

Peter J. Claude, Advisory Partner, PricewaterhouseCoopers

Steven Hutchins, Vice President, Business Development, WuXi AppTec
Ravi Kiron, Managing Director, Adjuvant Global Advisors, LLC
Kourosh Parivar, Head of Clinical Pharmacology, Oncology Business Unit Pfizer Global
Research & Development, Pfizer, Inc.
Peter G. Ulrich, Co-Founder, President & CEO, TargeGen

10:45 a.m. - 11:00 a.m.Networking Break

11:00 a.m. - 12:30 p.m.Workshops

Raising Money in Asia

Sponsored by: DLA Piper
Are there opportunities for a western company to raise money in Asia? This panel will focus on the growing financial community interested in investing in the biopharmaceutical industry and where they are looking for deals.

Lisa A. Haile, Partner Co-Chair, Global Life Sciences Sector, DLA Piper

Rachel Gong, Healthcare Investment, Morningside Ventures
Anand Govindaluri, CEO, Go-Vin Holdings
Anula Jayasuriya, Managing Director, Evolvence India Life Science Fund
Mark Saad, Chief Financial Officer, Cytori Therapeutics

12:30 p.m. - 2:30 p.m.Plenary Session

Plenary Session:
M&A Is Here to Stay

M&A activity in the biopharmaceutical sector has been heating up for a number of years. Indeed, rollups have been a way to expand a pipeline or to acquire new technology for years. This trend continued and expanded through 2008 with more acquisitions led by Asian pharma companies. This panel will address some of the more notable deals and their objectives and outcomes.


Ellen Foster Licking, Finance Bureau Chief, Elsevier Business Intelligence

Nancy Chang, Chairman and Sr. Managing Director, Asia, Orbimed Healthcare Fund Management
Zhu Shen, Chief Executive Officer, BioForesight
George Montgomery, Managing Director, Montgomery, Marshall Healthcare Partners
J. George Sarmiento, Senior Director, Business Development, Astellas Pharma Global Development

2:30 p.m. - 3:00 p.m.Networking Break

3:00 p.m. - 4:30 p.m.Workshops

Evolving Intellectual Property Rights in China and India

Sponsored by: Perkins Coie LLP
Intellectual property regulations have been a challenge and frequently a deterrent for western biopharmaceutical companies interested in doing business in Asia Pacific with a specific focus on China and India. This panel will discuss what has changed in each of these key markets and what changes they expect to see in the future.

Michael Wise, Chair, China Intellectual Property Practice, Perkins Coie LLP

Lisa Conte, CEO, Founder, Napo Pharmaceuticals
Rajeshwari Hariharan, Partner, K&S Partners
Chris Holloway, Group Director of Regulatory Affairs and Chief Scientific Officer, ERA Consulting
Stan Yakatan, Chairman, Co-Founder, Katan Associates

4:30 p.m. - 6:00 p.m.Closing Reception